Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-methylmesoporphyrin (NMM) is a synthetic porphyrin derivative and a member of the porphyrins class. It is primarily used as an experimental tool in research settings. Mechanistically it acts as a potent inhibitor of ferrochelatase—the enzyme responsible for catalyzing the insertion of iron into protoporphyrin IX during heme biosynthesis[1][4]. Additionally, NMM exhibits high selectivity for binding to G-quadruplex DNA structures over duplex or triplex DNA. Upon binding to G-quadruplexes (notably in telomeric and oncogene promoter regions), it stabilizes these structures and becomes highly fluorescent—making it valuable as a fluorescent probe for studying nucleic acid conformations and interactions[5][8]. Its applications include cancer research (due to its effects on gene expression via GQ stabilization), diagnostics (as a light-up probe), and studies on heme metabolism inhibition[5][9]. It is not approved for clinical use in humans.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-methylmesoporphyrin.